We balance proven methods with flexible thinking to create opportunity
A Specific Focus
We invest in early stage therapeutics, with later stage investments pursued selectively.
A Balanced Strategy
We pursue a balance between investing in breakthrough medical device and novel biopharmaceutical companies that have the potential to change medicine.
A Clear Advantage
We follow a thesis-driven investing process by which we proactively source opportunities through defined initiatives. This process has resulted in unique, deep strategic relationships and is reflected in some of the biggest life science winners in the past 10 years.
The result of our strategy is a long track record of achieving exits and delivering breakthrough therapies for patients.
Acceleron Pharma is a biopharmaceutical company focused on the development and commercialization of novel protein therapeutics for orphan diseases and cancer based on the TGF-β protein superfamily. The company had an IPO in 2013.
Altura is a medical device company focused on developing innovative devices and methods for the percutaneous treatment of abdominal aortic aneurysms (AAA). The company was acquired by Lombard Medical in 2015.
Acquired by Lombard Medical (NASDAQ: EVAR)
Ardian is a medical device company that developed a first-in-class renal denervation catheter for the treatment of hypertension. The company was incubated within The Foundry and was acquired by Medtronic in 2011.
Acquired by Medtronic (NYSE: MDT)
Avidia is a biopharmaceutical company focused on discovering and developing a new class of human therapeutic proteins called avimers™. The company was acquired by Amgen in 2006.
Aquired by Amgen (NASDAQ: AMGN)
Cabochon Aesthetics is a medical device company developing effective, scientific solutions for the aesthetic treatment of cellulite. The company was incubated within The Foundry and was acquired by Ulthera in 2014.
Acquired by Ulthera, Inc.
Calithera Biosciences is a biopharmaceutical company developing novel therapeutics for the treatment of cancer and other proliferative diseases by targeting the dysregulated metabolic pathways of cancer cells. The company had an IPO in 2014.
Catabasis is leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company had an IPO in 2015.
Catalyst Biosciences is developing therapeutics that utilize protease enzymes as biopharmaceuticals. Catalyst calls these redirected engineered proteases "Alterase™ Therapeutics." The company completed a reverse merger with Targacept in 2015.
FivePrime Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of a complete range of innovative protein and antibody drugs. The company had an IPO in 2013.
Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated initial human efficacy related to muscle cramping. The company had an IPO in 2015.
FoldRx Pharmaceuticals, Inc. is a biopharmaceutical company developing disease modifying drug therapies for diseases of protein misfolding and amyloidosis.
Acquired by Pfizer (NYSE: PFE)
VISION2 developed a proprietary ocular punctal plug drug delivery system. It is non-invasive and capable of delivering a variety of drugs to the eye through controlled release to the tear film.
Acquired by QLT, Inc. (NASDAQ: QLTI)
VISION4 is a medical device company focused on developing novel drug delivery therapies for treatment of retinal diseases. The company was incubated within ForSight Labs.
GI Dynamics is a medical device company developing a device to treat metabolic disease with gastric bypass. The company had an IPO on the Australian Securities Exchange in 2011.
Hypnion is a biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders such as sleep, wake-alertness disorders, circadian rhythm abnormalities.
Acquired by Eli Lilly (NYSE: LLY)
IVS is a medical device company developing a femoral artery closure device using a memory-metal clip to achieve hemostasis at the access site after a catheterization procedure.
Acquired by Abbott (NYSE: ABT)
MicroVention develops and markets innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels. The company was acquired by Terumo in 2006.
Acquired by Terumo (Tokyo Stock Exchange)
Miramar Labs is developing and marketing a non-invasive, lasting treatment for hyperhydrosis and excessive sweating using microwave energy. The company was incubated within The Foundry.
Morphotek is a biopharmaceutical company developing novel classes of biological-based products to treat cancer, inflammation and infectious diseases. The company was acquired by Eisai Inc. in 2007.
Acquired by Eisai (TYO: 4523)
Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences in 2016.
Lead program acquired by Gilead Sciences (NASDAQ: GILD)
OncoMed is developing monoclonal antibodies that target tumor initiating cells, also known as "cancer stem cells." The company had an IPO in 2013.
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for the treatment of obesity. The company had an IPO in 2007.
Plexxikon is developing novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of competitively differentiated therapeutic programs. The company was acquired by Daiichi Sankyo in 2011.
Acquired by Daiichi Sankyo (TYO: 4568)
Portola is developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company had an IPO in 2013.
Proteolix is a biopharmaceutical company developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
Acquired by Onyx (NASDAQ: ONXX)
Ra Pharmaceuticals is developing a new class of drugs with the specificity of antibodies and the oral bioavailability of small molecules. The company had an IPO in 2016.
Scioderm is focused on the development of innovative drugs for the treatment of chronic diseases of the skin. The company was acquired by Amicus Therapeutics in 2015.
Acquired by Amicus Therapeutics (NASDAQ: FOLD)
Threshold Pharmaceuticals is developing therapeutics based on tumor hypoxia, a platform that offers potential to treat most solid tumors. The company had an IPO in 2005.
Transcend Medical is a medical device company focused on the development of devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. The company was acquired by Alcon (Novartis) in 2016.
Acquired by Alcon (NYSE: NVS)
Twelve is a medical device company developing a novel device for the treatment of chronic cardiovascular disease. The company was incubated within The Foundry and was acquired by Medtronic in 2015.
Acquired by Medtronic (NYSE: MDT)
Verastem is bringing breakthroughs in cancer stem cell research into new medicines for the treatment of major cancers, such as breast cancer. The company had an IPO in 2012.
ZELTIQ is developing and marketing a non-invasive, office-based procedure that uses Cryolipolysis, a proprietary cooling technology, to eliminate fat. ZELTIQ had an IPO in 2011.